GlaxoSmithKline plc (NYSE:GSK) saw a significant decrease in short interest in November. As of November 30th, there was short interest totalling 10,397,225 shares, a decrease of 22.3% from the November 15th total of 13,387,745 shares. Based on an average trading volume of 4,254,511 shares, the short-interest ratio is currently 2.4 days. Currently, 0.4% of the shares of the company are sold short.
GlaxoSmithKline (NYSE GSK) opened at $34.99 on Monday. GlaxoSmithKline has a twelve month low of $34.52 and a twelve month high of $44.53. The company has a debt-to-equity ratio of 2.96, a current ratio of 0.64 and a quick ratio of 0.44. The company has a market capitalization of $86,052.55, a price-to-earnings ratio of 12.41, a PEG ratio of 1.94 and a beta of 0.98.
The business also recently declared a quarterly dividend, which will be paid on Thursday, January 11th. Stockholders of record on Friday, November 10th will be issued a $0.5037 dividend. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.49. This represents a $2.01 dividend on an annualized basis and a dividend yield of 5.76%. The ex-dividend date is Thursday, November 9th. GlaxoSmithKline’s dividend payout ratio (DPR) is presently 163.12%.
Several brokerages have weighed in on GSK. Cowen set a $38.00 price objective on GlaxoSmithKline and gave the company a “hold” rating in a report on Monday, December 11th. J P Morgan Chase & Co reissued a “neutral” rating on shares of GlaxoSmithKline in a report on Thursday, September 21st. Zacks Investment Research lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Tuesday, October 24th. Investec lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Monday, November 6th. Finally, Bank of America lowered GlaxoSmithKline from a “buy” rating to a “neutral” rating in a report on Thursday, October 26th. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $39.37.
In other GlaxoSmithKline news, major shareholder Plc Glaxosmithkline bought 428,571 shares of GlaxoSmithKline stock in a transaction dated Monday, November 6th. The stock was bought at an average cost of $14.00 per share, with a total value of $5,999,994.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 10.00% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. Parametric Portfolio Associates LLC raised its position in shares of GlaxoSmithKline by 6.8% in the third quarter. Parametric Portfolio Associates LLC now owns 1,452,468 shares of the pharmaceutical company’s stock worth $58,970,000 after buying an additional 92,125 shares in the last quarter. Shelton Capital Management raised its position in shares of GlaxoSmithKline by 73.5% in the third quarter. Shelton Capital Management now owns 28,331 shares of the pharmaceutical company’s stock worth $1,150,000 after buying an additional 12,000 shares in the last quarter. Steward Partners Investment Advisory LLC purchased a new stake in shares of GlaxoSmithKline in the third quarter worth $328,000. Belpointe Asset Management LLC purchased a new stake in shares of GlaxoSmithKline in the third quarter worth $204,000. Finally, Wealthcare Advisory Partners LLC raised its position in shares of GlaxoSmithKline by 1,982.8% in the third quarter. Wealthcare Advisory Partners LLC now owns 3,520 shares of the pharmaceutical company’s stock worth $143,000 after buying an additional 3,351 shares in the last quarter. 9.83% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “Short Interest in GlaxoSmithKline plc (GSK) Drops By 22.3%” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2017/12/18/short-interest-in-glaxosmithkline-plc-gsk-drops-by-22-3.html.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.